253 related articles for article (PubMed ID: 33083030)
1. Vaccine strategies for the
Sharan R; Kaushal D
NPJ Vaccines; 2020; 5():95. PubMed ID: 33083030
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials.
Wilson L; Gracie L; Kidy F; Thomas GN; Nirantharakumar K; Greenfield S; Manaseki-Holland S; Ward DJ; Gooden TE
BMC Infect Dis; 2023 Feb; 23(1):120. PubMed ID: 36829123
[TBL] [Abstract][Full Text] [Related]
4. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
[TBL] [Abstract][Full Text] [Related]
5. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
6. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
7. MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against
Broset E; Saubi N; Guitart N; Aguilo N; Uranga S; Kilpeläinen A; Eto Y; Hanke T; Gonzalo-Asensio J; Martín C; Joseph-Munné J
Mol Ther Methods Clin Dev; 2019 Jun; 13():253-264. PubMed ID: 30859110
[TBL] [Abstract][Full Text] [Related]
8. Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory.
da Costa AC; Nogueira SV; Kipnis A; Junqueira-Kipnis AP
Front Immunol; 2014; 5():152. PubMed ID: 24778634
[TBL] [Abstract][Full Text] [Related]
9. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.
Singh S; Saraav I; Sharma S
Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis vaccines: Opportunities and challenges.
Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
[TBL] [Abstract][Full Text] [Related]
13. Designing tuberculosis vaccine efficacy trials - lessons from recent studies.
Ginsberg AM
Expert Rev Vaccines; 2019 May; 18(5):423-432. PubMed ID: 30892969
[TBL] [Abstract][Full Text] [Related]
14. Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis.
Billeskov R; Tan EV; Cang M; Abalos RM; Burgos J; Pedersen BV; Christensen D; Agger EM; Andersen P
PLoS One; 2016; 11(8):e0161217. PubMed ID: 27525651
[TBL] [Abstract][Full Text] [Related]
15. Clinical Development of New TB Vaccines: Recent Advances and Next Steps.
Hatherill M; White RG; Hawn TR
Front Microbiol; 2019; 10():3154. PubMed ID: 32082273
[No Abstract] [Full Text] [Related]
16. Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.
Darrah PA; DiFazio RM; Maiello P; Gideon HP; Myers AJ; Rodgers MA; Hackney JA; Lindenstrom T; Evans T; Scanga CA; Prikhodko V; Andersen P; Lin PL; Laddy D; Roederer M; Seder RA; Flynn JL
NPJ Vaccines; 2019; 4():21. PubMed ID: 31149352
[TBL] [Abstract][Full Text] [Related]
17. MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic.
Gonzalo-Asensio J; Marinova D; Martin C; Aguilo N
Front Immunol; 2017; 8():1803. PubMed ID: 29326700
[TBL] [Abstract][Full Text] [Related]
18. Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes.
Joslyn LR; Pienaar E; DiFazio RM; Suliman S; Kagina BM; Flynn JL; Scriba TJ; Linderman JJ; Kirschner DE
Front Microbiol; 2018; 9():1734. PubMed ID: 30177914
[TBL] [Abstract][Full Text] [Related]
19. Prospects for a vaccine to prevent HIV-related tuberculosis.
Nemes E; Scriba TJ; Hatherill M
Curr Opin HIV AIDS; 2018 Nov; 13(6):522-527. PubMed ID: 30080682
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
